Format

Send to

Choose Destination
Rev Med Chil. 2017 Aug;145(8):963-971. doi: 10.4067/s0034-98872017000800963.

[Features, management and prognosis of Chilean patients with non valvular atrial fibrillation: GARFIELD AF registry].

[Article in Spanish]

Author information

1
División Enfermedades Cardiovasculares, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
2
Hospital Barros Luco Trudeau, Santiago, Chile.
3
Hospital del Salvador, Santiago, Chile.
4
Hospital Dr. Hernán Henríquez Aravena, Universidad de La Frontera, Temuco, Chile.
5
Hospital Base de Valdivia, Chile.
6
Hospital Carlos Van Buren, Valparaíso, Chile.
7
Hospital Base de Osorno, Chile.
8
Clínica Santa Lucía, Santiago, Chile.
9
Hospital Sótero del Río, Santiago, Chile.
10
Hospital Naval Almirante Nef, Valparaíso, Chile.
11
Hospital San Juan de Dios, La Serena, Chile.
12
Hospital Clínico de Magallanes Dr. Lautaro Navarro Avaria, Punta Arenas, Chile.
13
Hospital Clínico Regional Dr. Guillermo Grant Benavente, Concepción, Chile.
14
Hospital Regional de Talca, Chile.
15
Hospital Padre Alberto Hurtado, Santiago, Chile.

Abstract

BACKGROUND:

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with high rates of death, ischemic stroke and systemic embolism (SE). There is scarce information about clinical characteristics and use of anti-thrombotic therapies in Chilean patients with non-valvular AF.

AIM:

To describe the characteristics and 1-year outcomes of patients with recently diagnosed AF recruited in Chile into the prospective global GARFIELD-AF registry.

MATERIAL AND METHODS:

Between 2011-2016, we prospectively registered information of 971 patients recruited at 15 centers, 85% of them from the public system and 15% from the private sector. Demographics, clinical characteristics and use of antithrombotic therapies were recorded for all patients. Adverse clinical outcomes were analyzed in 711 patients with 1-year follow-up.

RESULTS:

The mean age was 71.5 years (66-79), 50% were men. Mean CHAD2S2 Vasc and HAS BLED scores for stroke risk were 3.3 (2.0-4.0) and 1.5 (1.0-2.0) respectively. Oral anticoagulants were prescribed in 82% of patients. Seventy percent received Vitamin K antagonists, 10% novel direct anticoagulants or antiplatelet therapy and only 8% did not receive any antithrombotic therapy. Mean time in optimal therapeutic range (an international normalized ratio of 2 to 3), was achieved in only 40.7% (23.0-54.8) of patients receiving Vitamin K antagonists. One year rates of death, stroke/systemic embolism and bleeding were 4.75 (3.36-6.71), 2.40 (1.47-3.92) and 1.64% (0.91-2.97) per 100 person-years. Ischemic stroke occurred in 1.8% and hemorrhagic stroke in 0.8% of patients at 1-year of follow up.

CONCLUSIONS:

Although the use of vitamin K antagonists at baseline was high, the mean time in optimal therapeutic range was low. Mortality and stroke rates are higher than those reported in other contemporary registries.

PMID:
29189853
DOI:
10.4067/s0034-98872017000800963
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online
Loading ...
Support Center